At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22,054 enrolled
Drug / intervention
Abaloparatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective, Observational Cohort Study Evaluating the Effectiveness and Cardiovascular Safety of Abaloparatide in Postmenopausal Women New to Anabolic Therapies
In Brief
An observational study evaluating Abaloparatide and Teriparatide for Osteoporosis, Postmenopausal. Completed, enrolled 22,054 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate the real-world effectiveness and cardiovascular safety of ABL compared with TPTD during the 18-month period after treatment initiation in propensity score (PS)-matched cohorts
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Postmenopausal
CountriesUnited States
CollaboratorsPRA Health Sciences
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartJul 2021
First PostedJul 2021
Primary CompletionSep 2021
TodayJul 2026
First PostedJul 23, 2021
Enrollment StartJul 1, 2021
Primary CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.9 years ago
Interventions
Abaloparatidedrug
Abaloparatide subcutaneous (abaloparatide SC \[ABL\]; Tymlos®)
Teriparatidedrug
Teriparatide subcutaneous (TPTD; Forteo®)